Publications by authors named "Neuzillet Y"
Objective: Renal oncocytoma is a benign renal tumour whose management remains heterogeneous and poorly codified. The aim of this study was to describe the management strategies and evolution of a cohort of biopsied renal oncocytomas.
Materials And Methods: We retrospectively reviewed renal oncocytomas biopsied in 2 French academic centres between 2009 and 2016.
Introduction: The purpose of this study was to propose an update of the French guidelines from the national committee ccAFU on upper tract urothelial carcinomas (UTUC).
Methods: A systematic Medline search for epidemiology, risk factors, diagnosis, prognosis, treatment options and follow-up of UTUC was performed between 2022 and 2024 to evaluate available references and their levels of evidence.
Results: UTUC is a rare malignancy with specific risk factors, including exposure to aristolochic acid and Lynch syndrome.
Objective: To update the CCAFU recommendations for the management of non-muscle invasive bladder cancer (NMIBC).
Methods: A systematic review (Medline) of the literature from 20222024 was performed, taking into account the elements of diagnosis, treatment options and monitoring of NMIBC and evaluating references with their level of evidence.
Results: The diagnosis of NMIBC (Ta, T1, or CIS) is made after complete and deep tumour resection.
Objective: To update the CCAFU recommendations for the management of muscle-invasive bladder cancer (MIBC).
Methods: A systematic review (Medline) of the literature from 2022 to 2024 was carried out, taking into account the elements of the diagnosis, the treatment options and the monitoring of NMIBC and MIBC, evaluating the references with their level of evidence.
Results: MIBC is diagosed after the must complete tumor resection possible .
Article Synopsis
- Metastatic urothelial carcinoma (mUC) is a dangerous cancer with few treatment options, and its genetic makeup is not fully understood unlike non-metastatic urothelial carcinoma (UC).
- A study analyzing genetic data from 111 mUC biopsies found that common genetic changes are similar to those seen in primary UC and highlighted mutational signatures related to APOBEC, platinum sensitivity, and homologous recombination deficiency.
- The research revealed that a significant portion of mUC patients have potential therapeutic targets, with the most common being FGFR3, ERBB2, TSC1, and PIK3CA, and noted that certain genes like NECTIN4 and TACSTD2 are consistently highly expressed across different
Article Synopsis
- In 2022, nivolumab was approved for high-risk patients with localized invasive muscle urothelial carcinoma after surgery, prompting a study to explore its real-world use.
- Conducted at two hospitals from July 2022 to January 2024, the study included 200 patients; 70 were deemed high-risk, but nearly half did not receive treatment due to various reasons.
- The outcomes showed a median disease-free survival of 11.34 months for treated patients, and while nivolumab was well-tolerated, 25% discontinued it due to side effects, with findings supporting prior research on its effectiveness.
Background And Objective: Failure rates after first-line treatment of localized prostate cancer (PCa) treatment remain high; therefore, it is essential to improve the selection and identification of at-risk patients to reduce mortality. The aim of the ANDROCAN study was to evaluate the biochemical recurrence (BCR) in patients with localized PCa treated by total prostatectomy at 5 yr after surgery, according to their presurgery gonadal status.
Methods: A prospective cohort study was conducted including 1318 patients undergoing total prostatectomy for localized PCa with a 5-yr postoperative follow-up.
Article Synopsis
- End-stage renal disease poses challenges for lung transplant patients, leading to the consideration of combined kidney-lung transplantation (CKLT) and kidney after lung transplantation (KALT) as potential solutions.
- A study reviewing outcomes of 26 patients showed that CKLT had a 30-day and 1-year survival rate of 75.6%, while no KALT patients died during follow-up, highlighting KALT's safety.
- The study found that kidney graft functions were similar between both strategies, but CKLT's success is significantly impacted by post-lung transplant complications, emphasizing the need for careful consideration of transplant options.
Background: Prognostic tools in pathological-node (pN) patients after radical cystectomy (RC) are needed.
Objectives: To evaluate the prognostic impact of lymph node (LN)-density on disease-specific survival (DSS) in patients with bladder cancer (BC) undergoing RC with pelvic lymph node dissection.
Methods: We analyzed a multi-institutional cohort of 1169 patients treated with upfront RC for cT1-4aN0M0 urothelial BCat nine centers.
Background And Objective: There is no standardized regimen for follow-up after radical cystectomy (RC) for bladder cancer (BC). To address this gap, we conducted a multicenter study involving urologist members from the European Association of Urology (EAU) bladder cancer guideline panels. Our objective was to identify consistent post-RC follow-up strategies and develop a practice-based framework based on expert opinion.
View Article and Find Full Text PDFBackground: Advances in chromatography and mass spectrometry have allowed us to develop a novel technique for measuring intraprostatic hormone concentrations directly on prostate needle biopsies, rather than using traditional punch excision. This has significant clinical implications as intraprostatic dihydrotestosterone and testosterone levels could help monitor prostate growth, neoplasia and castration resistance.
Methods: Patients undergoing radical cystoprostatectomy for bladder cancer were prospectively included.
Objective: To perform a collaborative review of the literature exploring the microsatellite instability/deficient mismatch repair (MSI/dMMR) phenotype in patients with upper tract urothelial carcinoma (UTUC).
Method: A collaborative review of the literature available on Medline was conducted by the Cancer Committee of the French Association of Urology to report studies describing the genetic mechanisms, investigation, prevalence and impact of the MSI/dMMR phenotype in UTUC patients.
Results: The predominant genetic mechanism leading to the MSI/dMMR phenotype in UTUC patients is related to the constitutional mutation of one allele of the MMR genes MLH1, MSH2, MSH6 and PMS2 within Lynch syndrome.
Article Synopsis
- The use of artificial intelligence (AI) in the medical field, especially in urology, is growing, enabling quicker access to current scientific knowledge which traditionally took years to master.
- In a study comparing the performance of AI tools (ChatGPT 3.5, ChatGPT 4.0, and Bard) against 736 human participants on a urological assessment, ChatGPT 4.0 performed the best, scoring 80 points and ranking near the top 10%.
- Despite showing promising results, the study emphasizes that current AI systems can make mistakes and highlights the need for careful evaluation of their role in medical education and information sharing.
Purpose: Bladder cancer is a complex disease with a wide range of outcomes. Clinicopathological factors only partially explain the variability between patients in prognosis and treatment response. There is a need for large cohorts collecting extensive data and biological samples to: (1) investigate gene-environment interactions, pathological/molecular classification and biomarker discovery; and (2) describe treatment patterns, outcomes, resource use and quality of life in a real-world setting.
View Article and Find Full Text PDFArticle Synopsis
- - The 2023 EAU guidelines provide updated, evidence-based recommendations for managing muscle-invasive and metastatic bladder cancer (MMIBC), focusing on diagnosis and treatment approaches.
- - Key findings emphasize the significance of detailed pathology reporting, using MRI for better disease staging, and the importance of evaluating frail patients with a team of specialists.
- - Treatment recommendations include cisplatin-based neoadjuvant therapy and exploring sexual organ-preserving surgeries, which lead to improved functional outcomes without increasing cancer risk.
Background: Upper urinary tract urothelial carcinoma (UTUC) is often locally advanced at initial diagnosis and is associated with high recurrence and mortality rates after radical nephroureterectomy (RNU). Adjuvant platinum-based chemotherapy has shown a recurrence-free survival benefit in a randomised phase III trial, while neoadjuvant treatment seems promising in retrospective series. On the contrary, little is known about the role of perioperative immunotherapy and its combination with chemotherapy for UTUC patients, although initial positive results have been published for muscle-invasive bladder cancer.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluated the effectiveness of a tension-free vaginal tape procedure for treating female stress urinary incontinence, aiming to compare its success with the occurrence of voiding dysfunction.
- Over a 1-year period, 93% of the 319 patients reviewed reported being dry, with a 10.9% incidence of voiding dysfunction noted.
- Factors linked to an increased risk of voiding dysfunction included having an underactive bladder, low preoperative urinary flow rate, and prior incontinence surgery, but overall, the procedure demonstrated a high cure rate and minimal serious complications.
Background: Darolutamide and enzalutamide are second-generation androgen receptor inhibitors with activity in men with castrate-resistant prostate cancer (CRPC) and different toxicity profiles.
Objective: ODENZA is a prospective, randomized, multicenter, cross-over, phase 2 trial designed to assess preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic CRPC (mCRPC).
Design, Setting, And Participants: Patients were randomized 1:1 to receive either darolutamide 1200 mg/d for 12 wk followed by enzalutamide 160 mg/d for 12 wk or enzalutamide followed by darolutamide.
Introduction: Endoscopic surgery is the standard treatment for benign prostatic hyperplasia (BPH) refractory to pharmacological treatments. In order to reduce invasiveness and preserve sexual function, prostatic artery embolization (PAE) has been developed. However, the technical difficulties of carrying out this procedure and the results, which have yet to be confirmed, mean that it is not currently recommended.
View Article and Find Full Text PDFIntroduction: Currently, bladder cancer detection is based on cytology and cystoscopy. White light cystoscopy (WLC) is an invasive procedure and may under-detect flat lesions. Blue light cystoscopy (BLC) and narrow band imaging (NBI) cystoscopy are new modalities that could improve the detection of non-muscle invasive bladder cancer (NMIBC) and its recurrence or progression to muscle invasive bladder cancer.
View Article and Find Full Text PDFMuscle-invasive bladder cancer (BLCA) is an aggressive disease. Consensus BLCA transcriptomic subtypes have been proposed, with two major Luminal and Basal subgroups, presenting distinct molecular and clinical characteristics. However, how these distinct subtypes are regulated remains unclear.
View Article and Find Full Text PDFObjectives: To evaluate variant histologies (VHs) for disease-specific survival (DSS) in patients with invasive urothelial bladder cancer (BCa) undergoing radical cystectomy (RC).
Materials And Methods: We analysed a multi-institutional cohort of 1082 patients treated with upfront RC for cT1-4aN0M0 urothelial BCa at eight centres. Univariable and multivariable Cox' regression analyses were used to assess the effect of different VHs on DSS in overall cohort and three stage-based analyses.
Introduction: Urachal cancer (UrC) is a rare, non-urothelial malignancy. Its natural history and management are poorly understood. Although localized to the bladder dome, the most common histological subtype of UrC is adenocarcinoma.
View Article and Find Full Text PDF